Young-Taek Sohn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Young-Taek Sohn has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Bo Ye Park
Duksung Women’s University
1 shared publicationJae-Keol Rhee
Dong-A Pharmaceutical Co. Ltd
1 shared publicationSun-Young Kim
Duksung Womenís University
1 shared publicationWeon-Bin Im
Dong-A Pharmaceutical Co. Ltd
1 shared publication
Latest Publications
- 1 July 2003
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 26 (7) , 526-531
Characterization of the physicochemical properties of KR-31378
- 1 July 2003
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 26 (7) , 526-531
Characterization of the physicochemical properties of KR-31378
- 1 August 2002
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 25 (4) , 556-559
Effect of crystal form onin vivo topical anti-inflammatory activity of corticosteroids
- 1 August 2002
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 25 (4) , 556-559
Effect of crystal form onin vivo topical anti-inflammatory activity of corticosteroids
- 1 August 2000
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 23 (4) , 381-384
Polymorphism of clarithromycin
It is well recognized that physicochemical properties of drugs are affected by the type of polymorphic crystalline form of drugs. Clarithromycin is known to exist in at least three polymorphic crystalline forms. Since conventional means to obtain the most thermodynamically stable form (Form II) for the antibiotics is known to be associated with a low purity of the stable form, we developed a novel method to improve the purity of the crystalline form by a modification of the preparation process. The new method involved a simple recrystallization of clarithromycin in solvents having 5–12 carbon atoms (e.g., hexane and heptane) or ethers with 4–10 carbon atoms (e.g., isopropyl ether) and, thus, less likely to be associated with the problem in purity of resulting crystal. Differential scanning calorimetry and powder X-ray diffraction were used to compare the crystalline form of the resultant powder with Form II crystal prepared by the conventional method. The crystal prepared by the new method was identical to Form II crystal of the conventional method as evidenced by the lack of the exothermic peak near 110°C in differential calorimetry scan, indicating that Form II crystal could be readily prepared by the new process. Therefore, these data indicated that the improvement in the purity of the Form II crystal for clarithromycin as well as a significant cost reduction is likely by the novel method.
- 1 August 2000
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 23 (4) , 381-384
Polymorphism of clarithromycin
It is well recognized that physicochemical properties of drugs are affected by the type of polymorphic crystalline form of drugs. Clarithromycin is known to exist in at least three polymorphic crystalline forms. Since conventional means to obtain the most thermodynamically stable form (Form II) for the antibiotics is known to be associated with a low purity of the stable form, we developed a novel method to improve the purity of the crystalline form by a modification of the preparation process. The new method involved a simple recrystallization of clarithromycin in solvents having 5–12 carbon atoms (e.g., hexane and heptane) or ethers with 4–10 carbon atoms (e.g., isopropyl ether) and, thus, less likely to be associated with the problem in purity of resulting crystal. Differential scanning calorimetry and powder X-ray diffraction were used to compare the crystalline form of the resultant powder with Form II crystal prepared by the conventional method. The crystal prepared by the new method was identical to Form II crystal of the conventional method as evidenced by the lack of the exothermic peak near 110°C in differential calorimetry scan, indicating that Form II crystal could be readily prepared by the new process. Therefore, these data indicated that the improvement in the purity of the Form II crystal for clarithromycin as well as a significant cost reduction is likely by the novel method.